Leading broker upgrades Ramsay (ASX:RHC) share price to buy rating

The good times could be returning for this healthcare giant…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Limited (ASX: RHC) share price was on form on Wednesday.

The private hospital operator's shares ended the day 2% higher at $63.49.

This means the Ramsay share price has now broken into positive territory for the year.

Young woman reviewing financial reports at desk with multiple computer screens.

Image source: Getty Images

Is the Ramsay share price in the buy zone?

One leading broker that believes the Ramsay share price is good value is Citi.

According to a note out of the broker yesterday, its analysts have upgraded the company's shares to a buy rating from neutral. Citi has also increased its price target from $67.00 up to $76.00.

Based on the latest Ramsay share price, this implies potential upside of almost 20% over the next 12 months excluding dividends. If you include them, this potential return stretches to over 22%.

Why did Citi upgrade Ramsay?

Citi made the move partly on valuation grounds, noting that the Ramsay share price has materially underperformed the ASX 200 in recent months and even after announcing its takeover approach of UK-based Spire Healthcare.

In addition to this, Citi is expecting the healthcare sector to return to normal in FY 2022, which it believes will lead to improving earnings. And while the broker suspects the Ramsay may need to raise capital in the future, it has factored this into its valuation.

Citi commented: "We are upgrading RHC to Buy post its bid for Spire Healthcare in the UK. The stock has fallen since the announcement, and has underperformed the ASX200 by 14% in the last quarter, and 40% over the last five years (making it the worst-performing ASX200 Healthcare company over that time frame). While the business currently remains severely impacted by the pandemic, we expect incremental news to be positive as health systems return to more normal conditions in FY22 and FY23."

James Mickleboro does not own any shares mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Woman checking out new laptops.
Broker Notes

3 reasons to buy the rebound in JB Hi-Fi shares today

A leading analyst suggests JB Hi-Fi shares are well-placed to outperform. But why?

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Broker Notes

Buy, hold, sell: Capricorn Metals, Chrysos, Cochlear shares

Analysts reveal their views on this gold miner, tech solutions provider, and healthcare share.

Read more »

Frustrated and shocked businesswoman reading bad news online from phone.
Broker Notes

Downgrade alert! 4 ASX shares re-rated by experts this week

Brokers reduced their ratings on Beach Energy, Jumbo Interactive, and other ASX stocks this week. 

Read more »

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Morgans says these ASX shares could rise 5%, 20%, and 55%

What is Morgans saying about these shares?

Read more »

A male broker wearing a dark blue suit and tie puts his finger to his lips to signal a secret tip about the Xero share price
Broker Notes

Buy, hold, sell: Karoon Energy, Brambles, REA shares

Experts reveal their ratings on three ASX shares in the energy, industrials, and communications sectors. 

Read more »

A man in a business suit holds his hand up to his mouth as though sharing a secret and gives a sly grin.
Broker Notes

Top broker just put a buy rating on this ASX share with 6.7% yield

Bell Potter has good things to say about this stock.

Read more »

Two brokers pointing and analysing a share price.
Broker Notes

1 ASX share to accumulate, one to hold, and one to sell

Morgans has given its verdict on the shares. Let's see what it is recommending.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Broker Notes

Forget PLS shares, this US-focused ASX lithium share could rise 100%+

Bell Potter sees potential for this lithium stock to more than double in value.

Read more »